Ebola natural history: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) |
||
| Line 17: | Line 17: | ||
*Patients often report significant improvement in clinical symptoms with adequate food intake and mobility.<ref name="pmid23327370">{{cite journal| author=Muyembe-Tamfum JJ, Mulangu S, Masumu J, Kayembe JM, Kemp A, Paweska JT| title=Ebola virus outbreaks in Africa: past and present. | journal=Onderstepoort J Vet Res | year= 2012 | volume= 79 | issue= 2 | pages= 451 | pmid=23327370 | doi=10.4102/ojvr.v79i2.451 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23327370 }} </ref> | *Patients often report significant improvement in clinical symptoms with adequate food intake and mobility.<ref name="pmid23327370">{{cite journal| author=Muyembe-Tamfum JJ, Mulangu S, Masumu J, Kayembe JM, Kemp A, Paweska JT| title=Ebola virus outbreaks in Africa: past and present. | journal=Onderstepoort J Vet Res | year= 2012 | volume= 79 | issue= 2 | pages= 451 | pmid=23327370 | doi=10.4102/ojvr.v79i2.451 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23327370 }} </ref> | ||
===Phase 2=== | ===Phase 2: Life-threatening Symptoms=== | ||
*A second phase of manifestations, characterized by hemorrhagic manifestations, typically develops during the peak of the illness. Approximately 50% of patients develop mucosal and visceral hemorrhage. | *A second phase of manifestations, characterized by hemorrhagic manifestations, typically develops during the peak of the illness. Approximately 50% of patients develop mucosal and visceral hemorrhage. | ||
*At advanced stages, patients' symptoms worsen, and they develop dyspnea, convlusions, diffuse coagulopathy, hypovolemic shock, and eventually death.<ref name="pmid9988154">{{cite journal| author=Peters CJ, LeDuc JW| title=An introduction to Ebola: the virus and the disease. | journal=J Infect Dis | year= 1999 | volume= 179 Suppl 1 | issue= | pages= ix-xvi | pmid=9988154 | doi=10.1086/514322 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9988154 }} </ref><ref name="pmid17940939">{{cite journal| author=Feldmann H, Geisbert T, Kawaoka Y| title=Filoviruses: recent advances and future challenges. | journal=J Infect Dis | year= 2007 | volume= 196 Suppl 2 | issue= | pages= S129-30 | pmid=17940939 | doi=10.1086/520550 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17940939 }} </ref><ref name="pmid21084112">{{cite journal| author=Feldmann H, Geisbert TW| title=Ebola haemorrhagic fever. | journal=Lancet | year= 2011 | volume= 377 | issue= 9768 | pages= 849-62 | pmid=21084112 | doi=10.1016/S0140-6736(10)60667-8 | pmc=PMC3406178 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21084112 }} </ref> | *At advanced stages, patients' symptoms worsen, and they develop dyspnea, convlusions, diffuse coagulopathy, hypovolemic shock, and eventually death.<ref name="pmid9988154">{{cite journal| author=Peters CJ, LeDuc JW| title=An introduction to Ebola: the virus and the disease. | journal=J Infect Dis | year= 1999 | volume= 179 Suppl 1 | issue= | pages= ix-xvi | pmid=9988154 | doi=10.1086/514322 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9988154 }} </ref><ref name="pmid17940939">{{cite journal| author=Feldmann H, Geisbert T, Kawaoka Y| title=Filoviruses: recent advances and future challenges. | journal=J Infect Dis | year= 2007 | volume= 196 Suppl 2 | issue= | pages= S129-30 | pmid=17940939 | doi=10.1086/520550 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17940939 }} </ref><ref name="pmid21084112">{{cite journal| author=Feldmann H, Geisbert TW| title=Ebola haemorrhagic fever. | journal=Lancet | year= 2011 | volume= 377 | issue= 9768 | pages= 849-62 | pmid=21084112 | doi=10.1016/S0140-6736(10)60667-8 | pmc=PMC3406178 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21084112 }} </ref> | ||
Revision as of 14:55, 27 October 2014
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola natural history On the Web |
|
American Roentgen Ray Society Images of Ebola natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Michael Maddaleni, B.S.; Guillermo Rodriguez Nava, M.D. [2] João André Alves Silva, M.D. [3]
Overview
Ebola infection rapidly progresses to death in the absence of supportive care. Ebola infection can be complicated by multiorgan failure and shock. Mortality rates, depending on the viral strain, can range between 25% - 90%.[1]
Natural History
The natural history of Ebola hemorrhagic fever is highly dependent on the Ebola virus species and the host immunity. The symptoms of Ebola hemorrhagic fever usually develop 2 to 21 days following exposure to Ebola virus. The clinical course of Ebola hemorrhagic fever has 2 phases, which may possibly be separated by a phase of "pseudoremission".[2] The clinical course of Ebola virus is a spectrum of manifestations. If left untreated, patients may remain asymptomatic or develop mild non-fatal disease, but the majority of patients develop severe symptoms that gradually worsen with time. Patients with non-fatal disease typically develop isolated high-grade fever that resolves within 6 to 11 days of disease onset. In contrast, fatal disease is associated with early clinical signs and symptoms, and these patients typically experience rapid clinical deterioration and die 6 to 16 days following the onset of symptoms.[3][4]
Phase 1: Early, Non-specific Symptoms
- Early symptoms include high-grade fever, chills, myalgias, arthritis, and generalized fatigue that develop within 6 to 11 days of viral incubation. Early symptoms typically persist for approximately one week.[5]
- Without treatment, patients subsequently develop non-specific multisystem symptoms, including constitutional (asthenia and anorexia), respiratory (cough and nasal discharge), and gastrointestinal manifestations (abdominal pain, nausea, and vomiting). *At day 5-7 following onset of symptoms, patients may develop cutaneous flushing or a characteristic desquematous, maculopapular, non-pruritic, erythematous rash with a centripetal distribution.
- Patients with non-fatal disease usually develop non-life-threatening symptoms that self-resolve approximately 7 to 10 days following onset of symptoms. When no improvement is observed within one week of phase 1 symptoms, patients are more likely to deteriorate into the potentially fatal phase 2 symptoms.[6]
Pseudoremission Phase
- A phase of pseudoremission, that typically occurs at day 7-8 of symptoms onset and lasts for 1 to 2 days, may be observed prior to the development of neurological and hemorrhagic manifestations.[2][5]
- Patients often report significant improvement in clinical symptoms with adequate food intake and mobility.[5]
Phase 2: Life-threatening Symptoms
- A second phase of manifestations, characterized by hemorrhagic manifestations, typically develops during the peak of the illness. Approximately 50% of patients develop mucosal and visceral hemorrhage.
- At advanced stages, patients' symptoms worsen, and they develop dyspnea, convlusions, diffuse coagulopathy, hypovolemic shock, and eventually death.[7][8][4]
Complications
Patients who survive Ebola infection may have the following complications:[4]
- Myalgias
- Headache
- Uveitis
- Tinnitis
- Hearing loss
- Psychosis
- Myelitis
- Recurrent hepatitis
- Amenorrhea
- Unilateral orchitis
- Suppurative parotitis
- Shock
Prognosis
- Ebola infection is associated with poor survival. Case-fatality rates is highly dependent on the species of virus:[4]
- Zaire Ebola virus species: case-fatality rate of 60 - 90%
- Sudan Ebola virus species: case-fatality rate 40 - 60%
- Bundibugyo Ebola virus species: case-fatality rate 25%
- Côte d’Ivoire Ebola virus: case-fatality rate 0% (only 1 case reported)
- Patients who survived Ebola infection for two weeks are usually able to recover slowly, despite potential complications.[4]
- Survival for 11 days is generally associated with recovery.
- Desquamation of the maculopapular rash by the 5th or 7th day is often associated with survival.[4]
- Tachypnea is the strongest correlate of fatal outcome. It often appears a few hours before death. Other correlates of fatal outcome are hypotension, tachycardia and anuria.
- Severe hemorrhagic complications such as hematemesis, melena, epistaxis, ear bleeding and hematuria are associated with a poorer prognosis and are often associated with death within a week.[9]
- In pregnant women there is an increased risk of miscarriage.[4]
References
- ↑ "CDC Ebola Hemorrhagic Fever Information Packet" (PDF). April 2010.
- ↑ 2.0 2.1 Ndambi R, Akamituna P, Bonnet MJ, Tukadila AM, Muyembe-Tamfum JJ, Colebunders R (1999). "Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995". J Infect Dis. 179 Suppl 1: S8–10. doi:10.1086/514297. PMID 9988156.
- ↑ Ksiazek TG, West CP, Rollin PE, Jahrling PB, Peters CJ (1999). "ELISA for the detection of antibodies to Ebola viruses". J Infect Dis. 179 Suppl 1: S192–8. doi:10.1086/514313. PMID 9988184.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Feldmann H, Geisbert TW (2011). "Ebola haemorrhagic fever". Lancet. 377 (9768): 849–62. doi:10.1016/S0140-6736(10)60667-8. PMC 3406178. PMID 21084112.
- ↑ 5.0 5.1 5.2 Muyembe-Tamfum JJ, Mulangu S, Masumu J, Kayembe JM, Kemp A, Paweska JT (2012). "Ebola virus outbreaks in Africa: past and present". Onderstepoort J Vet Res. 79 (2): 451. doi:10.4102/ojvr.v79i2.451. PMID 23327370.
- ↑ Casillas AM, Nyamathi AM, Sosa A, Wilder CL, Sands H (2003). "A current review of Ebola virus: pathogenesis, clinical presentation, and diagnostic assessment". Biol Res Nurs. 4 (4): 268–75. PMID 12698919.
- ↑ Peters CJ, LeDuc JW (1999). "An introduction to Ebola: the virus and the disease". J Infect Dis. 179 Suppl 1: ix–xvi. doi:10.1086/514322. PMID 9988154.
- ↑ Feldmann H, Geisbert T, Kawaoka Y (2007). "Filoviruses: recent advances and future challenges". J Infect Dis. 196 Suppl 2: S129–30. doi:10.1086/520550. PMID 17940939.
- ↑ Sureau PH (1989). "Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire". Rev Infect Dis. 11 Suppl 4: S790–3. PMID 2749110.